Guggenheim Maintains Buy on Vera Therapeutics, Lowers Price Target to $66
Benzinga Newsdesk 23 hours ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Vamil Divan maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and lowers the price target from $76 to $66.
Guggenheim analyst Vamil Divan maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and lowers the price target from $76 to $66.